Skip to content
OpenCapital
Get started

60 Degrees Pharmaceuticals SXTP Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

Revenue$261.4KBeat by $11.4K
EPS-$14.20Miss by $10.19
Revenue estimate$250.0K
EPS estimate-$4.01

Next report

Aug 12, 2026 (In 2 weeks)
Revenue estimate$185.0K
EPS estimate-$0.74

Versus estimates

Revenue

Q1 2026$162.1KMiss by $117.9KQ4 2025$300.0KMiss by $20.0KQ3 2025$437.6KBeat by $237.6KQ2 2025$100.9KMiss by $49.1KQ1 2025$163.6KMiss by $136.4K
Q4 2024$261.4KBeat by $11.4K

Diluted EPS

Q1 2026-$1.28Miss by $0.52Q4 2025-$1.91Beat by $0.37Q3 2025-$2.64Miss by $0.80Q2 2025-$1.25Miss by $0.01Q1 2025-$1.56Miss by $0.25
Q4 2024-$14.20Miss by $10.19

Ask the moment 60 Degrees Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did 60 Degrees Pharmaceuticals report Q4 2024 earnings?
60 Degrees Pharmaceuticals (SXTP) reported Q4 2024 earnings on March 27, 2025 before market open.
What were 60 Degrees Pharmaceuticals's Q4 2024 revenue and EPS?
60 Degrees Pharmaceuticals reported revenue of $261.4K and eps of $-14.20 for Q4 2024.
Did 60 Degrees Pharmaceuticals beat estimates in Q4 2024?
Revenue beat the consensus estimate of $250.0K by $11.4K. EPS missed the consensus estimate of $-4.01 by $10.19.
Where can I find 60 Degrees Pharmaceuticals's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001013762-25-003343) directly on SEC EDGAR. The filing index links above go to sec.gov.